Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chanaka Wickramasinghe

Cardiovascular Disease Rancho Mirage, CA Medical Doctor

NPI 1174840680 CMS profile 1381652

39000 Bob Hope Drive, Hal B. Wallis Bldg, Rancho Mirage, CA 92270

Open in the dashboard

General payments

$5,872

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,950 paid to institutions, not to them · program year 2025

Through program year 2025, Chanaka Wickramasinghe of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $5,872 across 158 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,950 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $835 33
2024 General $1,512 30
2023 General $688 24
2022 General $1,414 29
2021 General $734 22
2020 General $342 13
2019 General $346 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chanaka Wickramasinghe
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Chanaka Wickramasinghe were reported at $835. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Chanaka Wickramasinghe Cardiovascular Disease median Middle half National median
2019 $346 $450 $127–$1,392 $163
2020 $342 $242 $77–$751 $114
2021 $734 $335 $101–$1,037 $132
2022 $1,414 $395 $121–$1,211 $149
2023 $688 $443 $136–$1,283 $160
2024 $1,512 $450 $136–$1,323 $164
2025 $835 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,747 67 payments
  2. Boston Scientific Corporation $1,247 59 payments
  3. Bard Peripheral Vascular, Inc. $773 10 payments
  4. Acutus Medical, Inc. $286 3 payments
  5. Janssen Pharmaceuticals, Inc $167 5 payments
  6. Abiomed $157 1 payment
  7. BridgeBio Pharma, Inc. $135 1 payment
  8. Edwards Lifesciences Corporation $94 1 payment
  9. Novartis Pharmaceuticals Corporation $61 3 payments
  10. E.R. Squibb & Sons, L.L.C. $43 2 payments
  11. Other $162 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,480 150 payments
  2. Travel and Lodging $1,392 8 payments
Products named General payments · program years 2019–2025
  1. Venclose Maven Catheter $559 7 payments
  2. WATCHMAN Access System $475 27 payments
  3. WATCHMAN FLX $474 22 payments
  4. MITRACLIP Structural Heart $429 13 payments
  5. MitraClip System $368 11 payments
  6. MITRACLIP Vascular $262 12 payments
  7. TRICLIP $216 3 payments
  8. XARELTO $167 5 payments
  9. Impella $157 1 payment
  10. WATCHMAN $145 4 payments
  11. Other $1,126 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

7,591

Median for Cardiology: 2,533

Drug cost

$1,422,154

Median for Cardiology: $485,213

Branded share of claims

23.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 401 $512,612
Xarelto Rivaroxaban Brand 207 $252,655
Jardiance Empagliflozin Brand 158 $194,383
Repatha Sureclick Evolocumab Brand 104 $144,032
Entresto Sacubitril/Valsartan Brand 52 $68,926
Multaq Dronedarone Hcl Brand 34 $61,842
Praluent Pen Alirocumab Brand 29 $29,200
Rosuvastatin Calcium Generic 843 $16,370
Brilinta Ticagrelor Brand 21 $14,369
Vascepa Icosapent Ethyl Brand 23 $12,913

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$554,947

Medicare's payments for the services billed

Medicare patients

2,806

Average age 78

Services billed

17,020

1,303 women, 1,503 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 52%
Chronic kidney disease 38%
Atrial fibrillation 37%
Heart failure 32%
Diabetes 31%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record